In this Dec. 12, 2019 photo provided by Biogen, a scientist works on Alzheimer’s disease research in a laboratory at the drugmaker’s headquarters in Cambridge, Mass. On Friday, Nov. 6, 2020, a panel of outside experts will meet to advise the Food and Drug Administration on the drug, called aducanumab from Biogen Inc. and Japan’s Eisai Co. The drug does not cure or reverse Alzheimer’s; the claim is that it modestly slows the rate of decline. (David A. White/Biogen via AP)
Government health advisers sharply criticized a closely watched Alzheimer’s drug on Friday, concluding there wasn’t enough evidence that the experimental drug slowed the brain-destroying disease.
Efesbet, kullanıcı dostu bir platform sunarak oyuncuların rahatça bahis yapmalarını ve kazanç elde etmelerini sağlar. Kazandıran içeriklerle dolu platformlar, oyun severlerin ilk tercihleri arasında...
Bahis severler, en iyi platformlar sayesinde hızlı ödemeler ve cazip bonuslarla daha verimli bir oyun deneyimi yaşar. Kullanıcılar, platformların sunduğu deneme bonuslarıyla oyun dünyasına...
